Reset

Advanced Filters
03:30pm - 04:15pm EDT - March 19, 2021

Friday
03:30pm - 04:15pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Recognize the various types of uterine sarcomas and mixed epithelial/mesenchymal tumors.
  • Discuss the challenges of differentiating between these types of tumors.
  • Describe how molecular profiling can be used to help diagnose uterine sarcomas and carcinosarcomas, assess prognosis, and guide treatment decisions.
Friday
03:30pm - 04:15pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe the total neoadjuvant therapy approach for treating locally advanced rectal cancer and the results from clinical trials investigating this approach.
  • Discuss emerging treatment options for metastatic colorectal cancer and which patients might benefit from these new therapies based on clinical characteristics and biomarker results.
  • Apply clinical trial data into treatment strategies for locally advanced rectal cancer and metastatic colorectal cancer.
Friday


Objectives:
  • Review the treatment options for patients with relapsed or refractory CLL/SLL.
  • Discuss available evidence on sequencing therapy for patients with relapsed/refractory disease and develop an individualized treatment plan based on prior first-line therapy, disease-specific and patient-specific characteristics.
  • Describe the role of minimal residual disease (MRD) assessment and its implications on the management of patients with CLL/SLL.
Friday
03:30pm - 04:15pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe when systemic therapy may be appropriate for patients with thyroid carcinoma.
  • Identify systemic therapy options for advanced thyroid carcinoma.
  • Recognize side effects that are commonly reported in patients with thyroid carcinoma who are treated with systemic therapy.
04:15pm - 05:00pm EDT - March 19, 2021

Friday
04:15pm - 05:00pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe data from PARP inhibitor trials in patients with newly-diagnosed advanced ovarian cancer, and discuss how it may inform treatment and molecular testing in this setting.
  • Review factors that may impact the extent of clinical benefit from PARP inhibitor therapy.
  • Compare and contrast considerations for selecting recurrence therapy in patients who have progressed/recurred on or after PARPi maintenance.
Friday
04:15pm - 05:00pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Compare and contrast the differences between systemic therapy options available for first-line treatment of hepatobiliary cancers.
  • Describe how molecular profiling can help better inform clinical decision-making.
  • Identify the different options available for the treatment of hepatobiliary cancers based on the genetic abnormality detected.
Friday
04:15pm - 05:00pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Describe the current treatment approach and the rationale for the development of novel treatment options for relapsed/refractory B-cell lymphomas.
  • Review the efficacy of currently approved as well as investigational CAR T-cell therapies for relapsed or refractory B-cell lymphomas.
  • Evaluate the strategies for the management of unique toxicities associated with CAR T-cell therapies, and integrate CAR T-cell therapy into the overall treatment plan in appropriate patients with relapsed or refractory B-cell lymphomas.
Friday
04:15pm - 05:00pm EDT - March 19, 2021
Track: Clinical Updates in Oncology


Objectives:
  • Compare and contrast therapeutic approaches for treatment of salivary gland tumors.
  • Recognize when systemic therapy may be appropriate for patients with salivary gland tumors.
  • Evaluate the evidence supporting targeted treatment options for salivary gland tumors.